Skip to main content

Advertisement

Table 1 Patient characteristics

From: Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation

Variable All patients (n = 97) Low polyhedrocytes group (n = 14) High polyhedrocytes group (n = 83) p-value
Male sex, n (%) 63 (64.95) 11 (78.57) 52 (62.65) 0.37
Age, years 67.49 ± 8.82 70.64 ± 10.98 66.96 ± 8.36 0.15
Current smoking, n (%) 22 (22.68) 4 (28.57) 18 (21.69) 0.73
BMI, kg/m2 30.5 (27.4–34.4) 30.4 (28.1–35.7) 30.6 (27.2–34.1) 0.79
Hypertension, n (%) 93 (95.88) 13 (92.86) 80 (96.39) 0.47
Coronary artery disease, n (%) 74 (76.29) 11 (78.57) 63 (75.90) 1.00
T2D time since diagnosis, years 9.30 (5.75–14.30) 7.50 (5.25–15.00) 9.45 (6.00–13.98) 0.94
Drugs
 Sulphonylurea, n (%) 37 (38) 7 (50) 30 (36) 0.38
 Biguanide, n (%) 61 (63) 6 (43) 55 (66) 0.13
 Insulin, n (%) 25 (26) 4 (29) 21 (25) 0.75
 Beta-blocker, n (%) 82 (85) 12 (86) 70 (84) 1.00
 ACEI, n (%) 67 (69) 12 (86) 55 (66) 0.21
 Calcium antagonist, n (%) 32 (33) 3 (21) 29 (35) 0.38
 Clopidogrel, n (%) 22 (23) 5 (36) 17 (20) 0.30
 Aspirin, n (%) 79 (81) 13 (93) 66 (80) 0.46
 Statin, n (%) 80 (82) 14 (100) 66 (80) 0.12
 ARB, n (%) 17 (18) 2 (14) 15 (18) 1.00
 Loop diuretic, n (%) 30 (31) 6 (43) 24 (29) 0.35
 Spironolactone, n (%) 22 (23) 3 (21) 19 (23) 1.00
  1. Values are given as number (percentage), mean ± SD or median (interquartile range)
  2. Low polyhedrocytes group represents lowest 10% of the observations. High polyhedrocytes group represents highest 90% of the observations
  3. ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, BMI body mass index, MI myocardial infarction, T2D type 2 diabetes